Spassiba Vasya. We will respond shortly and will let you know when it's done.
Tom
Inviato dal mio dispositivo Samsung
-------- Messaggio originale --------
Da: Vasiliy Vlassov <[log in to unmask]>
Data: 04/09/2018 08:08 (GMT+01:00)
A: [log in to unmask]
Oggetto: Re: The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias
Thank you, Ahmed
Two main points of the DT response are (as I read it, probably
biased by my own perversions): 1) fuck off; 2) we would prefer to
manage it without involvement of the public.
Lets wait till the trusted three authors take next step. I am
quite sure they have words to say.
Vasya
On 2018-09-04 06:43, Manitoba Hunter
wrote:
<!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:848527212;
mso-list-template-ids:742003272;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
-->
I
just came across the response from Cochrane (https://www.cochrane.org/sites/default/files/public/uploads/cochrane_hpv_response_3sep18.pdf).
The highlights are also reported here (https://www.cochrane.org/news/cochranes-editor-chief-responds-bmj-ebm-article-criticizing-hpv-review)
mainly:
The Cochrane Review did not miss "nearly half
of the eligible trials". A small number of studies were
missed due to the primary focus on peer-reviewed reports
in scientific journals, but addition of these data makes
little or no difference to the results of the review for
the main outcome;
The trials comparators were unambiguously,
transparently, and accurately described;
The selection of outcomes for benefits was
appropriate and was consistent with World Health
Organization guidance;
The review included published and unpublished
data on serious harms, and the findings on mortality were
reported transparently and responsibly;
The review was compliant with Cochrane’s
current conflict of interest policy;
Cochrane’s media coverage was cautious and
balanced, but we recognize that there could be
improvements in relation to transparency where external
experts are quoted;
The
BMJ Evidence-Based Medicine article substantially
overstated its criticisms.
I
haven’t had a chance to read the rebuttal in full detail so
won’t comment but wanted to share so others can have a read
as well.
Cheers,
Ahmed
--
\/.\/.\/.
Vasiliy V. Vlassov, MD
President, Society for Evidence Based Medicine, osdm.org
Professor, National Research University Higher School of Economics
e-mail: vlassov[a t]cochrane.ru
Web page https://www.hse.ru/en/org/persons/14527416
snail mail: P.O.Box 13 Moscow 109451 Russia
Phone Russia +7(965)2511021
########################################################################
To unsubscribe from the EVIDENCE-BASED-HEALTH list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/webadmin?SUBED1=EVIDENCE-BASED-HEALTH&A=1
